JP2013518050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013518050A5 JP2013518050A5 JP2012550137A JP2012550137A JP2013518050A5 JP 2013518050 A5 JP2013518050 A5 JP 2013518050A5 JP 2012550137 A JP2012550137 A JP 2012550137A JP 2012550137 A JP2012550137 A JP 2012550137A JP 2013518050 A5 JP2013518050 A5 JP 2013518050A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- heteroaryl
- aryl
- ring
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33646010P | 2010-01-22 | 2010-01-22 | |
| US61/336,460 | 2010-01-22 | ||
| PCT/US2011/021982 WO2011091213A2 (en) | 2010-01-22 | 2011-01-21 | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016100346A Division JP2016153425A (ja) | 2010-01-22 | 2016-05-19 | タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013518050A JP2013518050A (ja) | 2013-05-20 |
| JP2013518050A5 true JP2013518050A5 (enExample) | 2016-05-12 |
| JP5940984B2 JP5940984B2 (ja) | 2016-06-29 |
Family
ID=44307593
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012550137A Expired - Fee Related JP5940984B2 (ja) | 2010-01-22 | 2011-01-21 | タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法 |
| JP2016100346A Pending JP2016153425A (ja) | 2010-01-22 | 2016-05-19 | タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016100346A Pending JP2016153425A (ja) | 2010-01-22 | 2016-05-19 | タンパク質デアセチラーゼ阻害剤としてのリバースアミド化合物とその使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US8394810B2 (enExample) |
| EP (2) | EP3091004B1 (enExample) |
| JP (2) | JP5940984B2 (enExample) |
| KR (1) | KR101808874B1 (enExample) |
| CN (3) | CN102933558B (enExample) |
| AU (1) | AU2016213729A1 (enExample) |
| BR (1) | BR112012018246B1 (enExample) |
| CA (1) | CA2787756C (enExample) |
| CL (1) | CL2012002026A1 (enExample) |
| CY (1) | CY1118156T1 (enExample) |
| DK (1) | DK2526093T3 (enExample) |
| EA (1) | EA026514B1 (enExample) |
| ES (1) | ES2592278T3 (enExample) |
| HR (1) | HRP20161367T1 (enExample) |
| HU (1) | HUE030679T2 (enExample) |
| LT (1) | LT2526093T (enExample) |
| MX (1) | MX2012008553A (enExample) |
| NZ (1) | NZ601655A (enExample) |
| PH (1) | PH12012501492B1 (enExample) |
| PL (1) | PL2526093T3 (enExample) |
| PT (1) | PT2526093T (enExample) |
| RS (1) | RS55227B1 (enExample) |
| SG (2) | SG10201500444TA (enExample) |
| SI (1) | SI2526093T1 (enExample) |
| SM (1) | SMT201600382B (enExample) |
| TW (3) | TWI600638B (enExample) |
| WO (1) | WO2011091213A2 (enExample) |
| ZA (1) | ZA201206063B (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2526093T3 (pl) * | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| WO2012018499A2 (en) * | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| CA2812855C (en) | 2010-10-08 | 2017-12-19 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| WO2012117421A1 (en) | 2011-03-02 | 2012-09-07 | Orchid Research Laboratories Ltd | Histone deacetylase inhibitors |
| FR2975911A1 (fr) * | 2011-06-06 | 2012-12-07 | Univ Strasbourg | Bisacodyl et analogues comme medicaments destines au traitement du cancer |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| KR101359571B1 (ko) | 2011-10-06 | 2014-02-10 | 서울대학교산학협력단 | Ｈｄａｃ 저해제와 알파칼슘설페이트를 유효성분으로 함유하는 치주질환 예방 및 치료용 약학적 조성물 |
| WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| HK1207403A1 (en) | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| WO2015054099A1 (en) * | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| WO2015054197A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| EP3055299B1 (en) * | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| ES2818933T3 (es) * | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| PE20161342A1 (es) | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| EP3060217B1 (en) * | 2013-10-24 | 2022-06-08 | Mayo Foundation for Medical Education and Research | Treatment of polycystic diseases with an hdac6 inhibitor |
| EP3076973B1 (en) * | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| TR201816176T4 (tr) | 2014-03-12 | 2018-11-21 | Chong Kun Dang Pharmaceutical Corp | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. |
| TW201625620A (zh) * | 2014-05-14 | 2016-07-16 | 美國科羅拉多州立大學 | 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 |
| CN107205988A (zh) * | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| CN107438436A (zh) | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| CA2970500C (en) | 2014-12-12 | 2023-08-29 | Acetylon Pharmaceuticals, Inc. | Piperidine derivatives as hdac1/2 inhibitors |
| WO2016126726A1 (en) | 2015-02-02 | 2016-08-11 | Forma Therapeutics, Inc. | Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors |
| TW201629026A (zh) | 2015-02-02 | 2016-08-16 | 佛瑪治療公司 | 作為ｈｄａｃ抑制劑的３－烷基雙環［４，５，０］異羥肟酸 |
| WO2016168647A1 (en) * | 2015-04-17 | 2016-10-20 | Acetylon Pharmaceuticals Inc. | Treatment of neuroblastoma with histone deacetylase inhibotrs |
| WO2016179398A1 (en) | 2015-05-05 | 2016-11-10 | Washington University | Isoform-selective lysine deacetylase inhibitors |
| MY195058A (en) | 2015-05-22 | 2023-01-05 | Chong Kun Dang Pharmaceutical Corp | Heterocyclicalkyl Derivative Compounds as Selective Histone Deacetylase Inhibitors and Pharmaceutical Compositions Comprising the Same |
| US10272084B2 (en) | 2015-06-01 | 2019-04-30 | Regenacy Pharmaceuticals, Llc | Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy |
| TWI706937B (zh) | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| AR104935A1 (es) * | 2015-06-08 | 2017-08-23 | Acetylon Pharmaceuticals Inc | Formas cristalinas de un inhibidor de histona deacetilasa |
| CN104974080A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
| CN104974084A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
| CN105017135A (zh) * | 2015-07-19 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 一类二吡啶叔醇结构的11β-HSD1抑制剂、制备方法及其用途 |
| NZ739211A (en) | 2015-07-27 | 2019-05-31 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same |
| BR112017027798B1 (pt) | 2015-07-27 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol sulfamida como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| HRP20230052T1 (hr) | 2015-07-27 | 2023-03-03 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| US10154997B2 (en) | 2015-08-04 | 2018-12-18 | Washington University | Treatment of parasitic diseases using KDAC inhibitor compounds |
| HRP20220003T1 (hr) | 2015-08-04 | 2022-04-01 | Chong Kun Dang Pharmaceutical Corp. | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
| US10040769B2 (en) * | 2015-10-27 | 2018-08-07 | Regenacy Pharmaceuticals, Llc | HDAC inhibitors for the treatment of diabetic peripheral neuropathy |
| WO2017142883A1 (en) * | 2016-02-16 | 2017-08-24 | The Board Of Trustees Of The University Of Illinois | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| US20170283445A1 (en) * | 2016-04-05 | 2017-10-05 | University Of South Carolina | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| EP3468559B1 (en) * | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| US10555935B2 (en) | 2016-06-17 | 2020-02-11 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors |
| JP7100018B2 (ja) * | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| US11357776B2 (en) | 2016-10-28 | 2022-06-14 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
| US11998546B2 (en) | 2016-10-28 | 2024-06-04 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof |
| PT3535275T (pt) | 2016-11-04 | 2022-08-26 | Acetylon Pharmaceuticals Inc | Combinações farmacêuticas compreendendo um inibidor de histona-desacetilase e um inibidor de bcl-2 e métodos de utilização das mesmas |
| EP3544612A4 (en) | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
| EP3544600A4 (en) * | 2016-11-23 | 2020-06-17 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS WITH A HISTONE DEACETYLAS INHIBITOR AND A PROGRAMMED DEATH LIGAND-1 (PD-L1) INHIBITOR AND METHOD FOR USE THEREOF |
| WO2019083960A1 (en) | 2017-10-24 | 2019-05-02 | Oncopep, Inc. | PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| KR102236356B1 (ko) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | 루푸스의 예방 또는 치료를 위한 조성물 |
| WO2019106633A1 (en) | 2017-12-01 | 2019-06-06 | University of Modena and Reggio Emilia | Methods of use and pharmaceutical combinations comprising histone deacetylase inhibitors and jak 1 2 inhibitors |
| ES2718240A1 (es) | 2017-12-28 | 2019-06-28 | Univ Del Pais Vasco / Euskal Herriko Unibertsitatea | Desarrollo de nuevos inhibidores selectivos frente a hdac6 derivados del acido ursodecoxicolico |
| WO2019139921A1 (en) | 2018-01-09 | 2019-07-18 | Shuttle Pharmaceuticals, Inc. | Selective histone deacetylase inhibitors for the treatment of human disease |
| KR20190099952A (ko) * | 2018-02-20 | 2019-08-28 | 주식회사 종근당 | 포도막염의 예방 또는 치료를 위한 조성물 |
| KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| CN110885316B (zh) * | 2018-09-10 | 2023-03-28 | 上海中泽医药科技有限公司 | 作为组蛋白去乙酰化酶抑制剂的巯基化合物及其用途 |
| CN111943892B (zh) * | 2019-05-17 | 2022-04-05 | 上海中泽医药科技有限公司 | 组蛋白去乙酰化酶亚型抑制剂硫乙酰芳胺类化合物及用途 |
| PH12021552930A1 (en) | 2019-05-31 | 2022-04-04 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| CN113874369B (zh) | 2019-05-31 | 2024-08-27 | 株式会社钟根堂 | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑高邻苯二甲酰亚胺衍生化合物及包含其的药物组合物 |
| US12630501B2 (en) | 2019-09-08 | 2026-05-19 | Hadasit Medical Research Services And Development Ltd. | Anti-fibrotic compounds and use thereof |
| KR102537616B1 (ko) | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102576148B1 (ko) | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102504830B1 (ko) | 2020-07-14 | 2023-03-02 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
| KR20230059801A (ko) | 2020-08-17 | 2023-05-03 | 알리고스 테라퓨틱스 인코포레이티드 | Pd-l1을 표적화하기 위한 방법 및 조성물 |
| KR102685058B1 (ko) | 2020-09-02 | 2024-07-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 새로운 구조의 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102905373B1 (ko) | 2021-04-08 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 싸이오카보닐 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102904231B1 (ko) | 2022-04-07 | 2025-12-29 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| CN114621754A (zh) * | 2022-04-18 | 2022-06-14 | 武汉轻工大学 | 一种荧光探针的制备及其在组蛋白去乙酰化酶中的应用 |
| CN119451953A (zh) | 2022-07-15 | 2025-02-14 | 株式会社 钟根堂 | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑三唑化合物和包含其的药物组合物 |
| JP2025533206A (ja) | 2022-10-14 | 2025-10-03 | チョン クン ダン ファーマシューティカル コーポレイション | ヒストンデアセチラーゼ６阻害剤としてのスルホキシイミン化合物及びそれを含む医薬組成物 |
| EP4673444A1 (en) | 2023-02-28 | 2026-01-07 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole derivative compounds, and the pharmaceutical composition comprising the same |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5837313A (en) | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| ZA9710342B (en) | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
| US5891507A (en) | 1997-07-28 | 1999-04-06 | Iowa-India Investments Company Limited | Process for coating a surface of a metallic stent |
| US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
| US6248127B1 (en) | 1998-08-21 | 2001-06-19 | Medtronic Ave, Inc. | Thromboresistant coated medical device |
| US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
| US6203551B1 (en) | 1999-10-04 | 2001-03-20 | Advanced Cardiovascular Systems, Inc. | Chamber for applying therapeutic substances to an implant device |
| US6251136B1 (en) | 1999-12-08 | 2001-06-26 | Advanced Cardiovascular Systems, Inc. | Method of layering a three-coated stent using pharmacological and polymeric agents |
| US20030129724A1 (en) | 2000-03-03 | 2003-07-10 | Grozinger Christina M. | Class II human histone deacetylases, and uses related thereto |
| JP2003528074A (ja) * | 2000-03-24 | 2003-09-24 | メチルジーン インコーポレイテッド | ヒストン脱アセチル化酵素の阻害剤 |
| WO2002074298A1 (en) * | 2001-03-21 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Il-6 production inhibitors |
| US7244853B2 (en) | 2001-05-09 | 2007-07-17 | President And Fellows Of Harvard College | Dioxanes and uses thereof |
| AU2002363174B2 (en) | 2001-11-01 | 2008-09-25 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| US6517889B1 (en) | 2001-11-26 | 2003-02-11 | Swaminathan Jayaraman | Process for coating a surface of a stent |
| US7154002B1 (en) * | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7375228B2 (en) | 2003-03-17 | 2008-05-20 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1644323B1 (en) | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
| CA2561617A1 (en) * | 2004-04-05 | 2005-10-20 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| SG171690A1 (en) | 2005-03-22 | 2011-06-29 | Harvard College | Treatment of protein degradation disorders |
| CA2620414A1 (en) | 2005-08-26 | 2007-03-01 | Methylgene Inc. | Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase |
| WO2008091349A1 (en) | 2006-02-14 | 2008-07-31 | The President And Fellows Of Harvard College | Bifunctional histone deacetylase inhibitors |
| WO2007130429A2 (en) | 2006-05-03 | 2007-11-15 | The President And Fellows Of Harvard College | Histone deacetylase and tubulin deacetylase inhibitors |
| WO2007144341A1 (en) * | 2006-06-12 | 2007-12-21 | Vrije Universiteit Brussel | Differentiation of rat liver epithelial cells into hepatocyte-like cells |
| ES2288802B1 (es) * | 2006-07-07 | 2008-12-16 | Universidad De Granada | Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas. |
| WO2008033746A2 (en) * | 2006-09-11 | 2008-03-20 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
| TWI478709B (zh) * | 2008-02-19 | 2015-04-01 | Earnest Medicine Co Ltd | A useful oral or enteral composition for the recovery of bodily functions |
| EP2321264B1 (en) | 2008-07-23 | 2016-05-04 | President and Fellows of Harvard College | Deacetylase inhibitors and uses thereof |
| US8716326B2 (en) * | 2009-05-15 | 2014-05-06 | Korea Research Institute Of Chemical Technology | Isoindolinone derivatives, preparation method thereof and a pharmaceutical composition comprising same |
| US8716344B2 (en) | 2009-08-11 | 2014-05-06 | President And Fellows Of Harvard College | Class- and isoform-specific HDAC inhibitors and uses thereof |
| WO2011084991A2 (en) | 2010-01-08 | 2011-07-14 | President And Fellows Of Harvard College | Fluorinated hdac inhibitors and uses thereof |
| PL2526093T3 (pl) | 2010-01-22 | 2017-02-28 | Acetylon Pharmaceuticals, Inc. | Odwrócone związki amidowe jako inhibitory deacetylazy białkowej oraz sposoby ich stosowania |
| EP2571352A4 (en) | 2010-05-21 | 2014-09-17 | Sloan Kettering Inst Cancer | SELECTIVE HDAC HEMMER |
| WO2012018499A2 (en) | 2010-08-05 | 2012-02-09 | Acetylon Pharmaceuticals | Specific regulation of cytokine levels by hdac6 inhibitors |
| NZ610225A (en) | 2010-11-16 | 2015-08-28 | Acetylon Pharmaceuticals Inc | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2734500A4 (en) | 2011-07-20 | 2015-04-08 | Gen Hospital Corp | SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS |
| HK1207403A1 (en) * | 2012-04-19 | 2016-01-29 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| US20140357512A1 (en) | 2013-06-03 | 2014-12-04 | Acetylon Pharmaceuticals, Inc. | Histone deacetylase (hdac) biomarkers in multiple myeloma |
| WO2015054099A1 (en) * | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| WO2015054197A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma |
| ES2818933T3 (es) | 2013-10-10 | 2021-04-14 | Acetylon Pharmaceuticals Inc | Inhibidores de la HDAC en combinación con los inhibidores de la pi3k, para el tratamiento del linfoma no Hodgkin |
| EP3055299B1 (en) | 2013-10-10 | 2021-01-06 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| PE20161342A1 (es) | 2013-10-11 | 2016-12-31 | Acetylon Pharmaceuticals Inc | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
| EP3076973B1 (en) | 2013-12-03 | 2020-04-29 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| CN107205988A (zh) * | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| TWI706937B (zh) * | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| US10040769B2 (en) * | 2015-10-27 | 2018-08-07 | Regenacy Pharmaceuticals, Llc | HDAC inhibitors for the treatment of diabetic peripheral neuropathy |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| EP3468559B1 (en) * | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| JP7100018B2 (ja) * | 2016-08-08 | 2022-07-12 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストンデアセチラーゼ６阻害剤及びｃｄ２０阻害抗体の薬学的組み合わせならびにその使用 |
| US11357776B2 (en) * | 2016-10-28 | 2022-06-14 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and an aurora kinase inhibitor and methods of use thereof |
| EP3544612A4 (en) * | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
-
2011
- 2011-01-21 PL PL11735212T patent/PL2526093T3/pl unknown
- 2011-01-21 SI SI201130938A patent/SI2526093T1/sl unknown
- 2011-01-21 NZ NZ601655A patent/NZ601655A/en unknown
- 2011-01-21 US US13/010,974 patent/US8394810B2/en active Active
- 2011-01-21 CN CN201180015409.5A patent/CN102933558B/zh active Active
- 2011-01-21 PH PH1/2012/501492A patent/PH12012501492B1/en unknown
- 2011-01-21 SG SG10201500444TA patent/SG10201500444TA/en unknown
- 2011-01-21 TW TW104134007A patent/TWI600638B/zh not_active IP Right Cessation
- 2011-01-21 EA EA201290677A patent/EA026514B1/ru unknown
- 2011-01-21 SG SG2012053930A patent/SG182646A1/en unknown
- 2011-01-21 RS RS20160849A patent/RS55227B1/sr unknown
- 2011-01-21 TW TW100102235A patent/TWI511732B/zh active
- 2011-01-21 EP EP16158086.5A patent/EP3091004B1/en active Active
- 2011-01-21 PT PT117352120T patent/PT2526093T/pt unknown
- 2011-01-21 CA CA2787756A patent/CA2787756C/en active Active
- 2011-01-21 MX MX2012008553A patent/MX2012008553A/es active IP Right Grant
- 2011-01-21 DK DK11735212.0T patent/DK2526093T3/en active
- 2011-01-21 WO PCT/US2011/021982 patent/WO2011091213A2/en not_active Ceased
- 2011-01-21 EP EP11735212.0A patent/EP2526093B1/en active Active
- 2011-01-21 HR HRP20161367TT patent/HRP20161367T1/hr unknown
- 2011-01-21 HU HUE11735212A patent/HUE030679T2/en unknown
- 2011-01-21 LT LTEP11735212.0T patent/LT2526093T/lt unknown
- 2011-01-21 ES ES11735212.0T patent/ES2592278T3/es active Active
- 2011-01-21 CN CN201610108022.9A patent/CN105727298A/zh active Pending
- 2011-01-21 TW TW106121994A patent/TW201735926A/zh unknown
- 2011-01-21 CN CN201610108094.3A patent/CN105753739A/zh active Pending
- 2011-01-21 JP JP2012550137A patent/JP5940984B2/ja not_active Expired - Fee Related
- 2011-01-21 BR BR112012018246-3A patent/BR112012018246B1/pt active IP Right Grant
- 2011-01-21 KR KR1020127021898A patent/KR101808874B1/ko active Active
- 2011-12-02 US US13/310,168 patent/US8148526B1/en active Active
-
2012
- 2012-04-02 US US13/437,672 patent/US8609678B2/en not_active Expired - Fee Related
- 2012-07-20 CL CL2012002026A patent/CL2012002026A1/es unknown
- 2012-08-13 ZA ZA2012/06063A patent/ZA201206063B/en unknown
-
2013
- 2013-11-11 US US14/076,596 patent/US20140142117A1/en not_active Abandoned
-
2014
- 2014-10-22 US US14/521,189 patent/US20150045380A1/en not_active Abandoned
-
2016
- 2016-05-19 JP JP2016100346A patent/JP2016153425A/ja active Pending
- 2016-08-09 AU AU2016213729A patent/AU2016213729A1/en not_active Abandoned
- 2016-09-12 US US15/262,899 patent/US20160375021A1/en not_active Abandoned
- 2016-10-26 SM SM201600382T patent/SMT201600382B/it unknown
- 2016-10-26 CY CY20161101080T patent/CY1118156T1/el unknown
-
2019
- 2019-08-26 US US16/550,763 patent/US11617750B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591775A1 (ru) | Замещенные ароматические соединения и связанный с ними способ лечения фиброза | |
| EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
| JP2015518055A5 (enExample) | ||
| RU2018106914A (ru) | 1,3,4,-оксадизоламидное производное соединение в качестве ингибитора гистондеацетилазы 6 и содержащая его фармацевтическая композиция | |
| JP2017537940A5 (enExample) | ||
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2016532667A5 (enExample) | ||
| EA201391158A8 (ru) | Диаминиевые соли фенотиазина и их применение | |
| EA201591774A1 (ru) | Замещенные ароматические соединения для лечения легочного фиброза, фиброза печени, фиброза кожи и фиброза сердца | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| JP2016534134A5 (enExample) | ||
| EP4583879B1 (en) | PYRIDAZINONE COMPOSITIONS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
| JP2016503786A5 (enExample) | ||
| EA201391629A1 (ru) | Ингибиторы цсж-1r для лечения опухолей головного мозга | |
| JP2016531113A5 (enExample) | ||
| EA201690094A1 (ru) | Ингибиторы syk | |
| EA201001159A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| EA201400358A1 (ru) | Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с | |
| AR101177A1 (es) | Inhibidores de la syk | |
| EA201290677A1 (ru) | Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения | |
| JP2013506639A5 (enExample) | ||
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| JP2013533253A5 (enExample) | ||
| EA201490552A1 (ru) | Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью |